1370290-34-8 Usage
General Description
AZ-33 is a proprietary organic corrosion inhibitor developed by the United States Navy for use in aircraft and ground support equipment. It is specifically designed to protect aluminum and other metals from corrosion in harsh operating environments, suchjson as saltwater exposure. AZ-33 has been shown to be effective in preventing and stopping corrosion on various metal surfaces, and it can be applied through spray or immersion methods. It also has the added benefit of being environmentally friendly and non-toxic, making it suitable for use in a wide range of applications. Overall, AZ-33 is a versatile and effective solution for protecting metal surfaces from corrosion in demanding conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1370290-34-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,0,2,9 and 0 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1370290-34:
(9*1)+(8*3)+(7*7)+(6*0)+(5*2)+(4*9)+(3*0)+(2*3)+(1*4)=138
138 % 10 = 8
So 1370290-34-8 is a valid CAS Registry Number.
1370290-34-8Relevant articles and documents
Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation
Ward, Richard A.,Brassington, Claire,Breeze, Alexander L.,Caputo, Alessandro,Critchlow, Susan,Davies, Gareth,Goodwin, Louise,Hassall, Giles,Greenwood, Ryan,Holdgate, Geoffrey A.,Mrosek, Michael,Norman, Richard A.,Pearson, Stuart,Tart, Jonathan,Tucker, Julie A.,Vogtherr, Martin,Whittaker, David,Wingfield, Jonathan,Winter, Jon,Hudson, Kevin
, p. 3285 - 3306 (2012/06/01)
Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate, utilizing NADH as a cofactor. It has been identified as a potential therapeutic target in the area of cancer metabolism. In this manuscript we report our progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors. Fragment hits were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking. Also reported is their modification into cellular active compounds suitable for target validation work.
